The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Abstract
Ruxolitinib is a small-molecule inhibitor of the JAK kinases, which has been approved for the treatment of myelofibrosis, a rare myeloproliferative neoplasm (MPN), but clinical trials are also being conducted in inflammatory-driven solid tumors. Increased infection rates have been reported in ruxolitinib-treated patients, and natural killer (NK) cells are immune effector cells known to eliminate both virus-infected and malignant cells. On this basis, we sought to compare the effects of JAK inhibition on human NK cells in a cohort of 28 MPN patients with or without ruxolitinib treatment and 24 healthy individuals. NK cell analyses included cell frequency, receptor expression, proliferation, immune synapse formation, and cytokine signaling. We found a reduction in NK cell numbers in ruxolitinib-treated patients that was linked to the appearance of clinically relevant infections. This reduction was likely due to impaired maturation of NK cells, as reflected by an increased ratio in immature to mature NK cells. Notably, the endogenous functional defect of NK cells in MPN was further aggravated by ruxolitinib treatment. In vitro data paralleled these in vivo results, showing a reduction in cytokine-induced NK cell activation. Further, reduced killing activity was associated with an impaired capacity to form lytic synapses with NK target cells. Taken together, our findings offer compelling evidence that ruxolitinib impairs NK cell function in MPN patients, offering an explanation for increased infection rates and possible long-term side effects associated with ruxolitinib treatment. Cancer Res; 75(11); 2187–99. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Cited by
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900321 · Cited by 21
Metadata
- Authors
- Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., Brümmendorf, T. H., Brossart, P., Heine, A., & Wolf, D.
- Venue
- Cancer Research
- Published
- 2015-05-31
- Volume
- 75
- Issue
- 11
- Pages
- 2187-2199
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2054787206
- Cited by
- 181
- References
- 6
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3198
- The paper
- Schönberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A. R., Uhrberg, M., Verbeek, W., Koschmieder, S., Brümmendorf, T. H., Brossart, P., Heine, A., & Wolf, D. (2015). JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.